Orion Oyj (ORINF)
USD 48.65
(0.0%)
USD 48.65
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 1.54 EUR | -38.15% |
| 2022 | 2.49 USD | 58.6% |
| 2021 | 1.57 EUR | -17.8% |
| 2020 | 1.91 EUR | 19.37% |
| 2019 | 1.60 EUR | 11.11% |
| 2018 | 1.44 EUR | -10.56% |
| 2017 | 1.61 EUR | -9.04% |
| 2016 | 1.77 EUR | 9.94% |
| 2015 | 1.61 EUR | 7.33% |
| 2014 | 1.50 EUR | 2.74% |
| 2013 | 1.46 EUR | -0.68% |
| 2012 | 1.47 EUR | -1.34% |
| 2011 | 1.49 EUR | 13.74% |
| 2010 | 1.31 EUR | 22.43% |
| 2009 | 1.07 EUR | 10.31% |
| 2008 | 0.97 EUR | -4.9% |
| 2007 | 1.02 EUR | 117.02% |
| 2006 | 0.47 EUR | -49.46% |
| 2005 | 0.93 EUR | 45.31% |
| 2004 | 0.64 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 0.34 EUR | -42.59% |
| 2024 Q2 | 0.37 EUR | 19.35% |
| 2024 Q3 | 1.27 EUR | 208.11% |
| 2023 Q1 | 0.34 USD | 41.67% |
| 2023 FY | - EUR | -38.15% |
| 2023 Q4 | 0.59 EUR | 28.26% |
| 2023 Q3 | 0.46 USD | 64.29% |
| 2023 Q2 | 0.28 USD | -17.65% |
| 2022 Q3 | 1.39 EUR | 183.67% |
| 2022 FY | - USD | 58.6% |
| 2022 Q2 | 0.49 EUR | 19.51% |
| 2022 Q4 | 0.24 USD | -82.73% |
| 2022 Q1 | 0.41 EUR | 78.26% |
| 2021 Q4 | 0.23 EUR | -28.13% |
| 2021 Q1 | 0.50 EUR | 176.24% |
| 2021 Q2 | 0.47 EUR | -6.0% |
| 2021 Q3 | 0.32 EUR | -31.91% |
| 2021 FY | - EUR | -17.8% |
| 2020 Q3 | 0.37 EUR | -31.48% |
| 2020 Q1 | 0.48 EUR | 50.0% |
| 2020 Q2 | 0.54 EUR | 12.5% |
| 2020 FY | - EUR | 19.37% |
| 2020 Q4 | 0.18 EUR | -51.08% |
| 2019 Q2 | 0.29 EUR | -3.33% |
| 2019 Q1 | 0.30 EUR | -21.05% |
| 2019 FY | - EUR | 11.11% |
| 2019 Q4 | 0.32 EUR | -37.25% |
| 2019 Q3 | 0.51 EUR | 75.86% |
| 2018 FY | - EUR | -10.56% |
| 2018 Q4 | 0.38 EUR | 58.33% |
| 2018 Q3 | 0.24 EUR | -81.82% |
| 2018 Q2 | 1.32 EUR | 221.95% |
| 2018 Q1 | 0.41 EUR | 5.13% |
| 2017 Q4 | 0.39 EUR | 25.81% |
| 2017 Q3 | 0.31 EUR | -22.5% |
| 2017 Q2 | 0.40 EUR | -20.0% |
| 2017 Q1 | 0.50 EUR | 47.06% |
| 2017 FY | - EUR | -9.04% |
| 2016 Q3 | 0.52 EUR | 10.64% |
| 2016 Q4 | 0.34 EUR | -34.62% |
| 2016 Q1 | 0.45 EUR | 60.71% |
| 2016 Q2 | 0.47 EUR | 4.44% |
| 2016 FY | - EUR | 9.94% |
| 2015 Q3 | 0.32 EUR | -21.95% |
| 2015 FY | - EUR | 7.33% |
| 2015 Q4 | 0.28 EUR | -12.5% |
| 2015 Q2 | 0.41 EUR | -12.77% |
| 2015 Q1 | 0.47 EUR | 62.07% |
| 2014 Q3 | 0.35 EUR | -27.08% |
| 2014 Q1 | 0.37 EUR | -6.57% |
| 2014 Q4 | 0.29 EUR | -17.14% |
| 2014 FY | - EUR | 2.74% |
| 2014 Q2 | 0.48 EUR | 29.73% |
| 2013 Q1 | 0.39 EUR | 28.29% |
| 2013 FY | - EUR | -0.68% |
| 2013 Q2 | 0.33 EUR | -15.38% |
| 2013 Q4 | 0.40 EUR | 13.14% |
| 2013 Q3 | 0.35 EUR | 6.06% |
| 2012 FY | - EUR | -1.34% |
| 2012 Q1 | 0.42 EUR | 30.84% |
| 2012 Q4 | 0.30 EUR | -24.0% |
| 2012 Q3 | 0.40 EUR | 14.29% |
| 2012 Q2 | 0.35 EUR | -16.67% |
| 2011 Q1 | 0.49 EUR | 87.74% |
| 2011 Q3 | 0.34 EUR | 0.0% |
| 2011 Q4 | 0.32 EUR | -5.59% |
| 2011 FY | - EUR | 13.74% |
| 2011 Q2 | 0.34 EUR | -30.61% |
| 2010 Q3 | 0.37 EUR | 19.35% |
| 2010 Q4 | 0.26 EUR | -29.46% |
| 2010 Q1 | 0.37 EUR | 58.12% |
| 2010 FY | - EUR | 22.43% |
| 2010 Q2 | 0.31 EUR | -16.22% |
| 2009 Q2 | 0.26 EUR | -13.33% |
| 2009 FY | - EUR | 10.31% |
| 2009 Q4 | 0.23 EUR | -19.31% |
| 2009 Q3 | 0.29 EUR | 11.54% |
| 2009 Q1 | 0.30 EUR | 0.0% |
| 2008 FY | - EUR | -4.9% |
| 2007 FY | - EUR | 117.02% |
| 2006 FY | - EUR | -49.46% |
| 2005 FY | - EUR | 45.31% |
| 2004 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AstraZeneca PLC | 3.84 USD | 59.896% |
| Bristol-Myers Squibb Company PFD CONV 2 | 3.88 USD | 60.309% |
| CSPC Pharmaceutical Group Limited | 0.07 USD | -2100.0% |
| Clarus Therapeutics Holdings, Inc. | -8.04 USD | 119.154% |
| Novartis AG | 7.63 USD | 79.817% |
| PT Kalbe Farma Tbk. | 0.00 USD | -39387.179% |